Loading company…
Beijing-based medical service provider focused on accurate infection diagnosis through pathogen sequencing.
Established in 2019 and based in Beijing, China, WILLINGMED provides accurate infection diagnosis, with main products including Plseq (Pathogen Identification Sequencing) metagenomic testing and the WYSP high-throughput automation workstation, which covers sample preparation, library construction, sequencing and clinical report generation. Founder and CEO Dr. Yan Zhang previously served as dean of the Institute of Translational Medicine at Boao Biology. In April 2023 it raised USD 14.53 million in Series B funding from Galaxy Capital Management, Haier Capital and Hunan Hi-Tech Venture Capital Health & Elderly Care Fund Management Co., Ltd.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in